XOMA (Nasdaq: XOMA) provided an update on its gevokizumab development program. Based on results from the Company's Phase 2 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Hot Corp. News Hot FDA News Management Comments Momentum Movers Trader Talk Trading Halts

XOMA (XOMA) Target Cut to $9 at JefferiesMarch 5, 2014 8:37 AM XOMA (XOMA) Sinks Over 15% on Trade ResumptionMarch 4, 2014 5:29 PM XOMA (XOMA) to Resume Trading at 5:25PM ETMarch 4, 2014 5:04 PM XOMA Ltd (XOMA) Posts Q4 GAAP Loss of 55c/ShareMarch 4, 2014 5:00 PM XOMA Provides Update on Gevokizumab Proof-of-Concept ProgramMarch 4, 2014 4:37 PM